Abstract
This month, a third agent joined vemurafenib and trametinib as a highly effective treatment for BRAF -mutated melanomas. In a prospective, randomized phase III study, the selective BRAF inhibitor dabrafenib was found to improve the survival of stage IV melanoma patients. The investigators …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have